jRCT2061200033进行中（未招募）不适用
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (T-DXd) VERSUS TRASTUZUMAB EMTANSINE (T-DM1) IN SUBJECTS WITH HIGH-RISK HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN BREAST OR AXILLARY LYMPH NODES FOLLOWING NEOADJUVANT THERAPY
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,600
- 主要终点
- Invasive Disease-free Survival (IDFS)
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Adults >=18 years old. (Follow local regulatory requirements if the legal age of consent for study participation is >18 years old.)
- •Pathologically documented HER2-positive BC:
- •HER2-positive expression defined as an immunohistochemistry (IHC) score of 3+ and/or positive by in situ hybridization (ISH) confirmed prior to study randomization.
- •Histologically confirmed invasive breast carcinoma.
- •Clinical stage at disease presentation: T1-4, N0-3, M0 (Note: Patients presenting with T1N0 tumors will not be eligible).
- •Pathologic evidence of residual invasive carcinoma in the breast and/or axillary lymph nodes following completion of neoadjuvant therapy meeting one of the following high-risk criteria.
- •Inoperable breast cancer at presentation (prior to neoadjuvant therapy), defined as clinical stages T4, N0-3, M0 or T1-3, N2-3, M
- •Operable at presentation, defined as clinical stages T1-3,N0-1,M0, with axillary node positive disease (ypN1-3) following neoadjuvant therapy.
- •Completion of neoadjuvant systemic chemotherapy, including taxane and HER2-directed treatment prior to surgery.
- •Systemic therapy must consist of at least 6 cycles of chemotherapy with a total duration of at least 16 weeks, including at least 9 weeks of trastuzumab (+/- pertuzumab) and at least 9 weeks of taxane based chemotherapy. Patients may have received an anthracycline as part of neoadjuvant therapy in addition to taxane chemotherapy.
- •Adequate excision as confirmed per medical records: surgical removal of all clinically evident disease in the breast and lymph nodes.
- •An interval of no more than 12 weeks between the date of last surgery and the date of randomization.
- •Known HR status, per local laboratory assessment, as defined by ASCO-CAP guidelines (>=1%): HR-positive status defined by either positive estrogen receptor (ER) and/or positive progesterone receptor (PR) status. HR-negative status defined by both known negative ER and known negative PR.
- •Left ventricular ejection fraction (LVEF) >=50% within 28 days prior to randomization.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at Screening.
- •Has adequate organ function within 14 days before randomization.
排除标准
- •Stage IV (metastatic) BC.
- •History of any prior (ipsi- or contralateral) breast cancer except lobular carcinoma in situ (LCIS).
- •Evidence of clinically evident gross residual or recurrent disease following neoadjuvant therapy and surgery.
- •Prior treatment with T-DXd, T-DM1 or other anti-HER2 antibody-drug conjugate (ADC)
- •History of exposure to the following cumulative doses of anthracyclines:
- •Doxorubicin > 240 mg/m2
- •Epirubicin or Liposomal Doxorubicin-Hydrochloride > 480 mg/m2
- •For other anthracyclines, exposure equivalent to doxorubicin > 240 mg/m2
- •History of other malignancy within the last 5 years except for appropriately treated CIS of the cervix, non-melanoma skin carcinoma, Stage I melanoma skin carcinoma, Stage I uterine cancer, or other appropriately treated non-breast malignancies.
- •History of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids and/or has ILD/pneumonitis noted on computed tomography (CT) scan of the chest at Screening (asymptomatic interstitial changes confined to recent radiation therapy fields are not excluded).
- •Known pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli within three months prior to randomization, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease).
- •Any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (eg, Rheumatoid arthritis, Sjogren's, sarcoidosis, etc.), or prior lobectomy or pneumonectomy.
- •Medical history of myocardial infarction within 6 months before randomization, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV), troponin levels consistent with myocardial infarction as defined according to the manufacturer 28 days prior to randomization.
结局指标
主要结局
Invasive Disease-free Survival (IDFS)
IDFS in participants who were administered Trastuzumab Deruxtecan (T-DXd) compared with Trastuzumab Emtansine (T-DM1) treatment
次要结局
- Disease-free Survival (DFS)
- Overall Survival (OS)
- Distant Recurrence-free Interval (DRFI)
- Brain Metastases-free Interval (BMFI)
- Percentage of Treatment-emergent Adverse Events
- Serum Concentrations of Trastuzumab Deruxtecan (T-DXd), total anti-HER2 antibody, and Active Metabolite MAAA-1181a
- Percentage of Participants Positive for Treatment-emergent Anti-drug Antibodies (ADAs)
研究者
相似试验
进行中（未招募）
2 期
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLCHER2-mutant Non-Small Cell Lung CancerNCT05246514AstraZeneca72
招募中
不适用
Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior PyrotinibBreast CancerNCT06135194Beijing 302 Hospital30
进行中（未招募）
3 期
德曲妥珠单抗（T-DXd）治疗激素受体阴性和激素受体阳性的 HER2 低表达或 HER2 IHC 0 乳腺癌（BC）受试者CTR2024364060
已完成
不适用
Trastuzumab deruxtecan for subjects with HER2-overexpressing advanced or metastatic CRC (DESTINY-CRC02)jRCT2051200124DAIICHI SANKYO Co.,Ltd.120
进行中（未招募）
不适用
Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or After a Trastuzumab-Containing RegimenjRCT2031200369DAIICHI SANKYO Co.,Ltd.490